Skip to content

Study · Case report or series · n = 1 · 2020

2 results

A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report.

Wu S, Wang J, Jing L, Chen L

Frontiers in endocrinology28 Jan 2021Cited by 10 (Europe PMC)

PMID33584541 (opens in a new tab)PMCIDPMC7876378 (opens in a new tab)DOI10.3389/fendo.2020.608966 (opens in a new tab)PepBankPUB-33584541
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

BackgroundDiabetes and cancer are both multifactorial diseases, and epidemiologic evidence indicates that diabetes may be associated with the incidence of certain types of cancer. In diabetes the risk of pancreatic cancer is increased significantly. However, whether certain diabetes treatment being related with the risk of pancreatic cancer remains unclear. In this report, we presented a case of pancreatic ductal adenocarcinoma in a diabetic patient in China after being treated with liraglutide, a novel glucagon-like peptide-1 (GLP-1) analog.Case reportA 71-year-old Han Chinese man who had had a type 2 diabetes for 25 years presented at the endocrinology department with discomfort in the left upper quadrant of abdomen for 10 days. The patient's vital signs and laboratory findings were unremarkable except for the elevated level of carbohydrate antigen (CA19-9). The upper abdomen routine enhanced computed tomography (CT) scan showed low density of the pancreatic body and tail, and the histopathological result of the pancreatic biopsy samples was pancreatic ductal adenocarcinoma with regional lymph node metastasis. We reviewed his former medical records and found that liraglutide was added to his hypoglycemic treatment regimen 20 months ago. At that time, the level of tumor biomarkers and upper abdomen routine CT were unremarkable. We estimated the causality between liraglutide and pancreatic cancer by the Naranjo Adverse Drug Reaction Probability scale and WHO-Uppsala Monitoring Centre (WHO-UMC) system, and the causality turned out to be possible.ConclusionOur report suggests that liraglutide may be related with the genesis and development of pancreatic cancer and also highlights the importance of regular checkups in diabetic patients treated with liraglutide. However, our report has some notable limitations, and further longer-term follow-up trials with larger sample should be conducted in future to assess the causality between liraglutide and pancreatic cancer.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 71-year-old man with type 2 diabetes, pancreatic ductal adenocarcinoma with regional lymph node metastasis was found about 20 months after liraglutide was added to his treatment.

    In plain wordsIn one older man with diabetes, pancreatic cancer was found about 20 months after liraglutide was added. This single case does not show cause.

    Peptide
    Liraglutide
    Outcome
    Not applicablePancreatic ductal adenocarcinoma after liraglutide
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated · 20 monthsAs given in this study (human).

    Source sentences

    Summary
    The upper abdomen routine enhanced computed tomography (CT) scan showed low density of the pancreatic body and tail, and the histopathological result of the pancreatic biopsy samples was pancreatic ductal adenocarcinoma with regional lymph node metastasis. We reviewed his former medical records and found that liraglutide was added to his hypoglycemic treatment regimen 20 months ago.
    1 context sentence
    Summary · context
    A 71-year-old Han Chinese man who had had a type 2 diabetes for 25 years presented at the endocrinology department with discomfort in the left upper quadrant of abdomen for 10 days.
  2. 02HumanCase report or seriesSafety outcome

    Naranjo and WHO-UMC assessments rated the causal link between liraglutide and pancreatic cancer in this patient as possible.

    In plain wordsTwo standard scoring tools rated a link between liraglutide and the cancer in this one patient as possible.

    Peptide
    Liraglutide
    Outcome
    Not applicableCausality assessment of liraglutide and pancreatic cancer
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We estimated the causality between liraglutide and pancreatic cancer by the Naranjo Adverse Drug Reaction Probability scale and WHO-Uppsala Monitoring Centre (WHO-UMC) system, and the causality turned out to be possible.
    1 context sentence
    Summary · context
    A 71-year-old Han Chinese man who had had a type 2 diabetes for 25 years presented at the endocrinology department with discomfort in the left upper quadrant of abdomen for 10 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.